FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

STOCKHOLM, Aug. 29, 2020 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides’ New Drug Application seeking approval of melflufen (INN melphalan flufenamide), in…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.